Is Neulasta a subsidiary?

No. Neulasta is a product brand owned by Amgen Inc., the drug it developed and markets.

Is Neulasta publicly traded?

No. Only the parent, Amgen Inc., is traded, on Nasdaq under ticker AMGN.

When was Neulasta approved?

Amgen received FDA approval for Neulasta in 2002 for chemotherapy-induced neutropenia.

What does Neulasta treat?

Neulasta prevents febrile neutropenia in cancer patients receiving chemotherapy, boosting white blood cell production to maintain immune function.

Neulasta is wholly owned by Amgen Inc., developed internally by the company.

What is Neulasta's market position?

Neulasta is the leading white blood cell stimulator for chemotherapy support, retaining majority share of the pegfilgrastim market despite biosimilar competition.

Healthcare & Pharmaceuticals

Who Owns Neulasta?

Neulasta (pegfilgrastim) is a biologic medication for chemotherapy-induced neutropenia owned by Amgen Inc. (Nasdaq: AMGN), the biotechnology company headquartered in Thousand Oaks, California. Approved in 2002, it is the leading white blood cell stimulator that helps cancer patients maintain immune function during chemotherapy. Parent FY2025 revenue was $36.8 billion.

Parent Company

Amgen Inc.

Founded

2002

Status

Publicly Traded

Headquarters

Thousand Oaks, California, USA (parent)

Neulasta Timeline

1980

Amgen Inc.

Parent company established in Thousand Oaks, California, USA

Company Founded

2002

Neulasta

Founded by Amgen (developer)

Founded

premiummarket leaderGlobalall-agesOfficial Website

Who Owns Neulasta?

Parent Company: Amgen Inc.
Ownership Type: Brand division
Company Type: Publicly Traded
Stock Ticker: NASDAQ: AMGN

Brand	Parent Company	Ownership Type
Neulasta	Amgen Inc.	Brand division

Where to Buy

Disclosure: We may earn commission from purchases

Neulasta on Amazon

History of Neulasta

Founded: 2002
Founders: Amgen (developer)

Amgen developed pegfilgrastim as a longer-acting version of filgrastim (Neupogen), attaching a polyethylene glycol molecule to extend its circulation time. The FDA approved Neulasta in 2002 for chemotherapy-induced neutropenia.

The single-injection-per-cycle dosing transformed supportive cancer care: where Neupogen required daily injections after each chemotherapy cycle, Neulasta required just one, improving adherence and reducing the treatment burden on patients already dealing with cancer.

Neulasta became one of Amgen's largest products, reaching peak sales exceeding $4.5 billion annually as the standard of care for febrile neutropenia prevention across solid tumor chemotherapy regimens.

Biosimilar competition arrived in the US in 2018, earlier than for many biologics, and has compressed Neulasta's sales from peak while the brand retains significant share as the established market leader.

About Amgen Inc.

What does Amgen own?
Amgen owns the Amgen brand and product brands including Enbrel, Prolia, Otezla, Neulasta, Repatha, Tezspire, and others. The Horizon acquisition added Tepezza, Krystexxa, and Uplizna.

Is Amgen publicly traded?
Yes. Amgen trades on Nasdaq under ticker AMGN and is a component of the S&P 500 and Dow Jones Industrial Average.

Who founded Amgen?
George Rathmann founded Applied Molecular Genetics in 1980 in Thousand Oaks, California. The name Amgen derives from the original.

Where is Amgen headquartered?
Amgen is headquartered in Thousand Oaks, California, USA.

Who owns Amgen?
Amgen is owned by public shareholders with no controlling investor. Robert Bradway serves as Chairman and CEO.

What is Amgen's revenue?
Amgen reported FY2025 total revenues of $36.8 billion, up 10%, with GAAP net income of $7.7 billion and non-GAAP EPS of $21.84.

What does Amgen make?
Amgen makes biologic medicines including Enbrel for rheumatoid arthritis, Prolia for osteoporosis, Otezla for psoriasis, and oncology and rare disease treatments.

Founded: 1980
Headquarters: Thousand Oaks, California, USA
Company Type: Publicly Traded
Stock: NASDAQ: AMGN
Revenue: $36.8 billion (FY2025)
Employees: Approximately 28,000

Visit Amgen Inc. website

View full company profile for Amgen Inc.

Where Is Neulasta Made / Based?

Headquarters: Thousand Oaks, California, USA (parent)
Manufacturing / Operations: United States, Puerto Rico

Neulasta Categories & Tags

Pharmaceuticals Biologics Oncology Chemotherapy Amgen

Neulasta Recalls & Controversies

As a pharmaceutical product, Neulasta's issues are pricing and competition-related.

Drug pricing: Neulasta's high US pricing drew scrutiny as part of the broader biologics affordability debate, with biosimilar entry eventually compressing the economics.

Patent exclusivity: Amgen's exclusivity defense delayed biosimilar entry as long as legally possible before competitors launched, the standard industry patent strategy.

Bone pain side effect: The class's characteristic bone pain side effect is a known tolerability issue managed through dosing guidance rather than a safety crisis.

Neulasta Ownership: Pros & Cons

Advantages

+Market leader in white blood cell stimulation for chemotherapy support
+Single-dose-per-cycle convenience distinguishes it from daily alternatives
+Onpro delivery device differentiates from biosimilar competitors
+Decades of established use create physician familiarity
+Still generates significant revenue despite biosimilar competition

Considerations

-Biosimilar competition has compressed sales from peak
-Mature oncology support market limits growth
-Multiple biosimilars now compete on price
-IRA pricing will eventually affect the brand
-Declining franchise value over time

Frequently Asked Questions About Neulasta

Sources & Further Reading

Competitors to Neulasta

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
AmgenSister Brand	Amgen	USA	1980	Market leader	Global	All-ages
EnbrelSister Brand	Amgen	USA (parent)	1998	Market leader	Global	All-ages
ProliaSister Brand	Amgen	USA (parent)	2010	Market leader	Global	All-ages
Eloxatin	Sanofi	France	2002	Generic available	Global	All-ages
Taxotere	Sanofi	France	1996	Established	Global	Unisex
OtezlaSister Brand	Amgen	USA (parent)	2014	Market leader	Global	All-ages